Medesis Pharma SA
Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nucl… Read more
Medesis Pharma SA (ALMDP) - Net Assets
Latest net assets as of June 2024: €-5.10 Million EUR
Based on the latest financial reports, Medesis Pharma SA (ALMDP) has net assets worth €-5.10 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.11 Million) and total liabilities (€7.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-5.10 Million |
| % of Total Assets | -242.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Medesis Pharma SA - Net Assets Trend (2018–2023)
This chart illustrates how Medesis Pharma SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medesis Pharma SA (2018–2023)
The table below shows the annual net assets of Medesis Pharma SA from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €-4.50 Million | -325.38% |
| 2022-12-31 | €-1.06 Million | -164.26% |
| 2021-12-31 | €1.65 Million | +179.04% |
| 2020-12-31 | €-2.08 Million | +13.87% |
| 2019-12-31 | €-2.42 Million | -176.03% |
| 2018-12-31 | €-876.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medesis Pharma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2071236900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.48 Million | % |
| Other Components | €14.75 Million | % |
| Total Equity | €-4.50 Million | 100.00% |
Medesis Pharma SA Competitors by Market Cap
The table below lists competitors of Medesis Pharma SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ju-Kao Engineering Co., Ltd.
TWO:1594
|
$1.54 Million |
|
Wheeler Real Estate Investment Trust Inc
NASDAQ:WHLR
|
$1.54 Million |
|
SWISS PRIME SITE N - Dusseldorf Stock Exchang
DU:SU1N
|
$1.54 Million |
|
Nam Viet JSC
VN:NAV
|
$1.54 Million |
|
Zinc8 Energy Solutions Inc
PINK:ZAIRF
|
$1.54 Million |
|
PT Adhi Karya (Persero) Tbk
F:KM6
|
$1.54 Million |
|
TrustBIX Inc
PINK:TBIXF
|
$1.54 Million |
|
Atrum Coal NL
AU:ATU
|
$1.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medesis Pharma SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -1,057,832 to -4,499,849, a change of -3,442,017.
- Net loss of 3,959,491 reduced equity.
- Other factors increased equity by 517,474.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.96 Million | -87.99% |
| Other Changes | €517.47K | +11.5% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Medesis Pharma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €-0.21 | €0.35 | x |
| 2019-12-31 | €-0.81 | €0.35 | x |
| 2020-12-31 | €-0.64 | €0.35 | x |
| 2021-12-31 | €0.38 | €0.35 | x |
| 2022-12-31 | €-0.24 | €0.35 | x |
| 2023-12-31 | €-0.91 | €0.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medesis Pharma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1319.68%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-26.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -9290.91% | 0.01x | 0.00x | €-934.40K |
| 2019 | 0.00% | -469.13% | 0.32x | 0.00x | €-837.20K |
| 2020 | 0.00% | -406.27% | 0.25x | 0.00x | €-638.82K |
| 2021 | -160.89% | -2766.62% | 0.02x | 2.63x | €-2.81 Million |
| 2022 | 0.00% | -5841.88% | 0.02x | 0.00x | €-2.66 Million |
| 2023 | 0.00% | -1319.68% | 0.16x | 0.00x | €-3.51 Million |
Industry Comparison
This section compares Medesis Pharma SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medesis Pharma SA (ALMDP) | €-5.10 Million | 0.00% | N/A | $1.54 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |